Fondaparinux Market Report 2025

The fondaparinux market size has grown strongly in recent years. It will grow from $1.85 billion in 2024 to $1.98 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to the rising incidence of venous thromboembolism, an increase in surgical procedures, an aging population, global healthcare improvements, and the growing preference for injectable anticoagulants.

The fondaparinux market size is expected to see strong growth in the next few years. It will grow to $2.62 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to the growing prevalence of obesity, rising awareness of thrombosis prophylaxis, government support and reimbursement policies, and growth in high-risk surgical procedures. Major trends in the forecast period include advanced drug delivery systems, pre-filled syringe technology, AI-enabled pharmacovigilance systems, biosynthetic manufacturing processes, and wearable drug delivery devices.

The forecast of 7.2% growth over the next five years reflects a modest reduction of 0.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to increase U.S. hospital costs for this synthetic anticoagulant by raising prices of pentasaccharide active pharmaceutical ingredients and prefilled syringes sourced from France and India, potentially reducing venous thromboembolism prophylaxis in surgical patients and raising perioperative care expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising incidence of thromboembolic conditions is expected to significantly drive the growth of the fondaparinux market. Thromboembolic conditions occur when blood clots form in blood vessels and obstruct blood flow to vital parts of the body. This increase in prevalence is largely attributed to the aging population, as older individuals are more susceptible to conditions such as deep vein thrombosis and pulmonary embolism due to slower blood circulation and other health-related issues. Fondaparinux is used to prevent and treat these conditions by inhibiting the formation of harmful blood clots. For example, in January 2025, the Centers for Disease Control and Prevention (CDC) reported that 60,000 to 100,000 fatalities occur annually in the United States due to venous thromboembolism (VTE), with many individuals suffering from long-term complications. Thus, the rising prevalence of thromboembolic conditions will continue to drive the growth of the fondaparinux market.

Rising healthcare expenditures are expected to fuel the growth of the fondaparinux market. Healthcare expenditures refer to the total financial outlay for medical services, treatments, and healthcare-related products by individuals, governments, and organizations. These rising expenditures are driven by an increased demand for advanced medical treatments and technologies, as well as the growing prevalence of chronic diseases and an aging population requiring more healthcare services. As demand for fondaparinux increases, especially for treating cardiovascular and thromboembolic conditions, healthcare costs also rise. For instance, in May 2024, the Office for National Statistics in the UK reported a 5.6% increase in healthcare expenditure from 2022 to 2023, a sharp rise compared to the 0.9% growth seen in 2022. Therefore, increasing healthcare expenditures will propel the growth of the fondaparinux market.

Key players in the fondaparinux market are focusing on innovations such as pediatric-specific drug development to expand the therapeutic applications of fondaparinux, address unmet medical needs, and enhance treatment options for younger patients with conditions such as venous thromboembolism (VTE). Pediatric drug development involves creating and adjusting medications to ensure they are safe and effective for children, considering their unique physiological and developmental requirements. For example, in December 2024, Mylan N.V., a US-based pharmaceutical company, received approval from the Food and Drug Administration (FDA) for Arixtra in treating VTE in pediatric patients aged 1 year and older, weighing at least 10 kg. Arixtra is also approved for adult conditions, including the prevention of deep vein thrombosis (DVT) and the treatment of acute DVT and pulmonary embolism. The pediatric approval was supported by a retrospective, open-label clinical study involving 366 patients, which showed that 44.9% of participants experienced complete resolution of at least one clot, while 44% had full resolution of all clots.

Major players in the fondaparinux market are Sanofi S.A., Abbott Laboratories Inc., GlaxoSmithKline plc, Viatris Inc., Mylan N.V., Sandoz Group AG, Sun Pharmaceutical Industries Limited, Jiangsu Hengrui Pharmaceuticals Co. Ltd., Cipla Limited, Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Limited, Aspen Pharmacare Holdings Limited, Lupin Pharmaceuticals Inc., Zydus Lifesciences Limited, Sihuan Pharmaceutical Holdings Group Ltd., Hefei TNJ Chemical Industry Co. Ltd., Apino Pharma Co. Ltd., Home Sunshine Pharma Co. Ltd., Alchemia Limited, Zhejiang Borui Pharmaceutical Co. Ltd.

North America was the largest region in the fondaparinux market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in fondaparinux report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the fondaparinux market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The fondaparinux market consists of sales of active pharmaceutical ingredient, injection, and fondaparinux kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment - many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The fondaparinux market research report is one of a series of new reports that provides fondaparinux market statistics, including the fondaparinux industry global market size, regional shares, competitors with the fondaparinux market share, detailed fondaparinux market segments, market trends, and opportunities, and any further data you may need to thrive in the fondaparinux industry. This fondaparinux market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Fondaparinux is a synthetic anticoagulant that works by selectively inhibiting Factor Xa, preventing the formation of blood clots. It is commonly used to reduce the risk of thromboembolic events in patients at risk.

The main uses of fondaparinux include treating deep vein thrombosis (DVT) and pulmonary embolism. Deep vein thrombosis (DVT) is a condition in which a blood clot forms in a deep vein, usually in the legs, and can lead to serious complications if left untreated. Fondaparinux is typically administered through various routes, including parenteral methods such as injections and pre-filled syringes. It is available in different dosage forms, primarily injections. The drug is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies. Key end users include hospitals, specialty clinics, and other healthcare providers.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.